Enhanced activation of cellular AMPK by dual-small molecule treatment: AICAR and A769662 PMC
The ROC curve was constructed and the area under the ROC curve (AUC) was calculated. “Five-week-old, pre-diabetic ZDF Zucker diabetic fatty rats underwent daily treadmill running or AICAR treatment over an 8-week period and were compared with an untreated group. “AMPK is a phylogenetically conserved serine/threonine protein kinase which has been proposed to act as a ‘metabolic master switch’ mediating the cellular adaptation to environmental or nutritional stress factors.
PTP1B is widely expressed in tissues but is highly present in the liver muscle and adipose tissue. It plays a critical role in regulating signal transduction pathways by removing phosphate groups from phosphotyrosine residues on target proteins. This action generally serves as a ‘turn-off’ switch for various signaling pathways. Is taken up into cells by adenosine transporters and phosphorylated by adenosine kinase to the active nucleotide ZMP (5-aminoimidazole-4-carboxamide ribonucleoside), which mimics effects of AMP on the AMPK system. The test was performed on half of the animals from each group two days before the planned necropsy.
Proteins and Peptides
The dosage was chosen based on previous in vivo rat studies that used between 0.5 and 1.0 g/kg body weight for chronic AICAR injections (18–20). Fifteen hours later, epididymal fat pads from each group were extracted, and adipocytes were isolated for analysis of palmitate oxidation (3) or protein expression by Western blotting. For in vivo glucose and NEFA determination, animals were injected with either saline or AICAR, and blood samples from the saphenous vein were collected at various time points. An 8 h time course was chosen for in vivo studies to avoid the effects of circadian rhythm on lipolytic rate (21).
In C57BL/6 mice kept on HFD, the baseline hyperglycemia was recorded—the initial blood glucose levels in groups 3, 4, 5, and 6 were significantly higher relative to animals from group 1 kept on a standard diet (STD + vehicle) and group 2 (STD + AC). The introduction of insulin significantly reduced the level of glucose in the blood from the initial values in each of the groups after 20 min. Hypoglycemia compared with the baseline values persisted until the end of the experiment.
In vivo treatment
- The ability to control inflammation could reduce the progression of vascular disease, including atherosclerosis.
- Enzymes involved in β-oxidation, such as carnitine palmitoyltransferase-1b (CPT-1b) and acetyl-CoA oxidase, were upregulated by ∼3.9- and 2.3-fold, respectively.
- The AMPK-stimulating AICAR can also be synthesized in a lab and is being evaluated in preclinical research and human clinical trials as a therapeutic agent to treat certain metabolic disorders in humans.
- In addition, it is susceptible to allosteric regulation with the participation of nucleotides, which is even more sophisticated in comparison with the PRPP synthase 40.
Membranes were blocked for 1 h in 10 mM Tris (pH 7.6), 137 mM NaCl, 0.1% (vol/vol) Tween 20 (TBST) containing 5% (wt/vol) skimmed milk. Membranes were incubated in primary antibody prepared in TBST containing 1% (wt/vol) BSA overnight at 4°C. Detection was performed with horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence reagent. AICAR has been shown to improve endurance and exercise stamina in a rat skeletal muscle study.
Similar to autophagy, but refers specifically to the process by which cells turnover mitochondria. The statistical analysis was assessed by either one-way analysis of variance, followed by post-hoc Bonferroni’s test, https://torneig.cotifalcudia.com/anabolic-mix-how-to-buy-2/ or Student’s t test. Myofiber number counts and size measurements were performed in bright field digital images taken from TA muscle cross-sections stained with H&E. Images were subsequently processed using ImageJ software (National Institutes of Health, Bethesda, MD, USA). At Direct Peptides, we are committed to quality and service, aiming to provide a safe, convenient, and discreet online shopping experience for research-grade peptides.
AMPK has emerged as a key drug target for metabolic disorders such as insulin resistance, cardiovascular disease, and type 2 diabetes (19). This is based on numerous reports demonstrating that activation of AMPK by physiological (e.g., exercise/muscle contraction) or pharmacological means brings about desirable effects that ameliorate metabolic dysfunctions by improving glycemic control and plasma lipid profiles (13, 28). Although a variety of compounds including several xenobiotics (which are known to elicit anti-obesity/diabetic effects) stimulate AMPK, it has been demonstrated that almost all of them with some exceptions (3, 11, 16) activate AMPK by an indirect mechanism (17). 5-Aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR) is a very widely used AMPK activator that is transported into the cell and phosphorylated to form ZMP, which mimics the effect of AMP by directly binding to the γ-subunit. We and others previously reported that not only does A directly activate AMPK but its binding (independently of canonical AMP/ZMP-binding sites) also prevents Thr172 dephosphorylation in a cell-free assay (10, 33).
In group 5 (HFD + AC 7), at week 11, there was a significant decrease in body weight gain relative to group 3 (HFD + vehicle) (38.6 ± 12.7% versus 52.0 ± 14.9%), which indicates that that AICAR treatment from seventh week of the study, helps to reduce body weight gain. The rate of weight gain in animals treated with HFD was significantly increased relative to the control starting from the fifth week of the study. This increase was maintained throughout the study in all animals on HFD, with the exception of the group 5 animals treated with AICAR from week 7 of the study. In general, it can be concluded that AICAR, administered starting from the seventh week of the study, contributes to the reduction in absolute body weight and weight gain in animals receiving HFD. We chose to use 30 μM, as opposed to 10 μM used in hepatoyctes, because our previous work (10) and pilot experiments (data not shown) revealed that the dose required to activate de novo AMPK (by monitoring ACC phosphorylation) is different among cell types.
